Evidence map›Paper›PMID 34233657›Full record

ArticleBMC endocrine disorders2021

The relationship between changes in serum myostatin and adiponectin levels in patients with obesity undergoing a weight loss program.

Nana Takao, Satoshi Kurose, Takumi Miyauchi, Katsuko Onishi, Atsuko Tamanoi, Ryota Tsuyuguchi, Aya Fujii, Sawako Yoshiuchi, Kazuhisa Takahashi, Hiromi Tsutsumi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Adiponectin Resistance in Obesity: Adiponectin Leptin/Insulin Interaction.Advances in experimental medicine and biology · 2024
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nana TakaoDepartment of Health Science, Graduate School of Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, 573-1010, Japan. takaonan@hirakata.kmu.ac.jp.
Satoshi KuroseDepartment of Health Science, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, 573-1010, Japan.
Takumi MiyauchiDepartment of Health Science, Graduate School of Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, 573-1010, Japan.
Katsuko OnishiDepartment of Health Science, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, 573-1010, Japan.
Atsuko TamanoiHealth Science Center, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata, 573-1191, Japan.
Ryota TsuyuguchiDepartment of Health Science, Graduate School of Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, 573-1010, Japan.
Aya FujiiDepartment of Health Science, Graduate School of Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, 573-1010, Japan.
Sawako YoshiuchiDepartment of Nutrition Management, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata, 573-1191, Japan.
Kazuhisa TakahashiDepartment of Medicine II, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, Japan.
Hiromi TsutsumiDepartment of Health Science, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, 573-1010, Japan.
Yutaka KimuraHealth Science Center, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata, 573-1191, Japan.
Kansai Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn effective strategy for weight loss in patients who are overweight or obese is to reduce body fat mass while maintaining skeletal muscle mass. Adiponectin and myostatin are affected through changes in body composition due to weight loss, and examining their dynamics may contribute to strategies for maintaining skeletal muscle mass through weight loss. We aimed to examine the relationships among myostatin, adiponectin, and body composition, depending on the extent of weight loss, in patients with obesity undergoing a weight loss program.

methodsWe examined 66 patients with obesity (age: 46.8 ± 14.0 years, body mass index: 34.3 [31.0-38.4] kg/m

resultsSerum myostatin and adiponectin levels increased post-intervention in both groups. Body weight and %fat decreased, and the rate of lean body mass (%LBM) increased in both groups. Exercise capacity and muscle strength improved in the M group only. Change in (⊿) myostatin correlated with ⊿%fat, ⊿%LBM, and ⊿adiponectin. ⊿adiponectin (β = - 0.262, p = 0.035) was an independent predictor of ⊿myostatin.

conclusionsMyostatin and adiponectin might cross-talk and regulate changes in skeletal muscle and fat mass with or without successful weight loss. These findings indicate that evaluating serum myostatin and adiponectin levels in clinical practice could be used to predict the effects of weight loss and help prevent skeletal muscle mass loss.

Indexed as

Weight Reduction ProgramsAdiponectinAdipose TissueAdultBody CompositionBody Mass IndexBody WeightExercise TestExercise TherapyFemaleHumansMaleMiddle AgedMuscle, SkeletalMuscle StrengthMyostatinAdiponectinMSTN protein, humanMyostatinAdiponectinBody compositionLean massMyostatinWeight loss

Identifiers

PMID34233657
PMCPMC8265051
OpenAlexW3136517606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.